Jubilant HollisterStier LLC

A joint venture between Vitrian, a provider of biomanufacturing facilities, and the Howard Hughes Corporation will bring manufacturing facilities to the Houston suburb of the Woodlands, TX. According to a press release, the area has several companies nearby, including Millipore Sigma and KBI Biopharma. The joint venture aims to meet the needs of local companies by providing a manufacturing facility in the Woodlands for use by local biotechs and CDMOs as well. According to Vitrian co-founder and managing principal Scott Nudelman, the company previously partnered with Cellipont Bioservices on its new HQ and manufacturing site in the Woodlands area, which is leading to a deeper commitment locale. However, no other details on the new project have been revealed as of yet. “The dynamic environment and amenity base created and nurtured by Howard Hughes provides a unique place to attract and retain life science companies and their workforce,” Nudelman said in the release . The National Health Service’s Blood and Transplant (NHSBT) division has opened the new facility, dubbed the Clinical Biotechnology Centre, located outside the city of Bristol, UK. The new center was established with a £10 million ($12.1 million) grant from the UK government. The new site is designed to make clinical-grade products for cell and gene therapy R&D. It will also manufacture products for diseases such as sickle cell, cystic fibrosis and some forms of cancer. “The CBC will help the UK grow its cell and gene therapy industry in a rapidly growing international market. We won’t be designing the treatments, but we will be manufacturing them to the right scale and clinical grade. Cell and gene therapy is a growing area for the healthcare sector and part of our direction of travel as an organisation,” said Lilian Hook, the NHSBTs director of cell, aphaeresis and gene therapies, in a release . The New Jersey-based radiopharmaceutical CDMO Evergreen Theragnostics has wrapped up a $15 million Series B raise. On the back of the funding, the CDMO is launching a new unit of its business, dubbed Evergreen Discovery. This unit will be focused on developing new radiopharmaceuticals for cancer therapy. The company has also hired Thomas Reiner as its chief scientific officer, who previously served as the head of radioligand therapy drug discovery at Advanced Accelerator Applications, a Novartis company. Evergreen Discovery will also be based in a new research facility near Princeton, NJ sometime in the third quarter of this year. “Launching Evergreen Discovery represented the next logical step for us, and we are excited to have recruited Thomas as a leader of this new team. With Evergreen Discovery, we will develop novel radiopharmaceuticals to address some of the most urgent unmet clinical needs,” said James Cook, President and CEO of Evergreen Theragnostics, in a release . Evergreen will also use the cash to prepare for the launch of Ga-68 DOTATOC if it is approved. The CDMO will be building out its commercial capabilities and staffing as well as preparing inventory. Sai Life Sciences has established a GMP “Kilo Lab” at its facility in Manchester, UK, allowing the company to offer drug substance supplies to its customers. The new lab will have the capacity to produce up to 35 liters of product, with room to add more capacity in the future, along with space for other analytical services to customers. “The new lab, located closer to our customers, has been set up with comprehensive cGMP controls and world-class infrastructure. The facility will combine with our expertise in route scouting, process chemistry and scale-up, to help our partners accelerate their drug discovery and development journeys by reducing time to first-in-human clinical trials,” said Sai Life Sciences COO Sauri Gudlavalleti, in a statement . The biotherapeutics CDMO GTP Bioways and the CRO Texcell, which specializes in assay development and GMP banking, are engaging in a partnership to provide end-to-end services to support the development of therapeutics to customers across the globe. The partnership will see GTP Bioways provide biomanufacturing and development services for customers ,while Texcell will provide greater international reach for the partnership with its offices and laboratories in France as well as China, Japan, the US and Germany. “Texcell and GTP Bioways share the same business philosophy. We are both science-driven and customer-centric companies and believe in empathy, integrity, and transparency to build the success of our customer’s programs. It is thus quite natural that our long business relationship turned into a deeper partnership,” said Alain Sainsot, president of GTP Bioways in a release . The cell and gene therapy CDMO Porton Advanced Solutions has secured a strategic partnership with Bennu Biotherapeutics with a goal to boost the development of T-cell therapies for tumors and autoimmune diseases. The terms of the agreement will see Proton providing CDMO services for multiple pipelines in cell and gene therapy, however, the financial terms of the timeline of the deal were not disclosed. “Through our end-to-end Cell and Gene Therapy CDMO, Porton Advanced aims to help Bennu Biotherapeutics develop multiple pipelines for cell therapy products, accelerate the development of innovative drugs such as TIL, and bring these beneficial drugs to market as soon as possible,” said Yangzhou Wang, CEO of Proton Advanced, in a release . The consulting outfit Cell One Partners and the CDMO Center for Breakthrough Medicines (CBM) have formed a strategic partnership to commercialize cell and gene therapies. The deal will aim to combine Cell One’s strategic capabilities and guidance of cell and gene therapy biotechs with the manufacturing of the Center for Breakthrough Medicines. “A strategic partnership with Cell One Partners provides CGT developers access to Cell One Partners’ virtual C-Suite executives and strategic advisors and access to CBM’s expansive capacity, breadth of CGT technologies, R&D, process development and GMP manufacturing expertise, allowing innovators to focus on research, extend cash runway, simplify a complex supply chain, and accelerate the development and manufacturing of their therapies,” said Jennifer Manning the SVP of global strategic partnerships at CBM, in a release . The Canadian manufacturer OmniaBio will be developing and producing Catamaran Bio’s allogenic CAR-NK cell therapies that are designed to treat solid tumors. The deal will see OmniaBio develop cell therapy at its sites in Toronto, which allows the manufacturer to go between development and manufacturing on a clinical scale. No other details on the deal were released. “This collaboration will allow us to develop scalable processes for the robust GMP manufacture of our off-the-shelf CAR-NK cell therapies,” says Alvin Shih, Catamaran Bio’s CEO in a release . Alcami has appointed Jamie Iudica to the position of chief manufacturing officer. Iudica has over 25 years of experience in the pharmaceutical world, having previously served as chief manufacturing officer at Istari Oncology. He has also served in several manufacturing and leadership positions at companies such as Pfizer, Hospira and Xellia Pharmaceuticals. “Jamie’s extensive expertise in drug product manufacturing operations will be integral as we expand the Alcami manufacturing and operations footprint,” said Alcami CEO Patrick Walsh, in a statement . Alcami also announced that COO Ken Domagalski will retire later this year. Jubilant HollisterStier has named Chris Preti as its new president. Preti has 25 years of experience in R&D, sales, marketing and operations. He was most recently the president of HollisterStier Allergy and has also held positions at GlaxoSmithKline. “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide,” Preti said in a statement emailed to Endpoints News .

Chris Preti Brings 25 Years of Broad Pharmaceutical Industry Experience to New Role Planned Capacity Expansion for New Sterile Injectables Line at Spokane Facility Progressing Well Meet Jubilant HollisterStier Representatives at 2023 DCAT Week to Learn More About its Integrated Injectable and Ophthalmic Drug Manufacturing Capabilities SPOKANE, Wash.--(BUSINESS WIRE)-- Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President. He brings more than 25 years of broad pharmaceutical industry experience to JHS. Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President. Chris holds a Bachelor of Science degree and Master of Science degree in Chemistry from Furman University and a Master of International Business Studies degree from the Darla Moore School of Business at the University of South Carolina. Chris also completed the program in Transformational Leadership for Executives at the Wharton School of the University of Pennsylvania. As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~285 million (USD) to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well. The investment is part of the company’s cooperative agreement providing 149.6 million (USD) from the US Government to expand its critical vaccine manufacturing capacity in the US. Chris Preti commented, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide. As a leading contract manufacturer of injectable pharmaceutical products and sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, we are acutely aware of the supply chain issues that continue to challenge manufacturers. With this expansion, we are well-positioned to address the contract manufacturing needs of major producers throughout North America. My decades in the Pharma industry taught me the critical role of manufacturing in achieving commercial success, and I am delighted to be heading up an industry leader committed to providing the highest quality comprehensive services in partnership with our customers.” About Jubilant HollisterStier Jubilant HollisterStier, a subsidiary of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full range of support to streamline manufacturing, from process qualifications through commercial release. For more information, please visit . About Jubilant Pharma Limited Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated markets, including USA, Europe, and other geographies. The Company has a team of around 3,500 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more information, please visit . Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time-to-time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. View source version on businesswire.com: Contacts JHS Corporate Contact Jen Beeler Jubilant HollisterStier jennifer.beeler@jubl.com (509) 873-4794 Debra Harrsch Brandwidth Solutions LLC dharrsch@brandwidthsolutions.com (215) 997-8575 Source: Jubilant HollisterStier View this news release online at:

A pharmaceutical contract manufacturer that has been growing its presence in the US has secured itself a sizable contract from the US government. Jubilant HollisterStier, a subsidiary of Singapore-based Jubilant Pharma Limited, has entered into a cooperative agreement for $149.6 million with the Army Contracting Command. The deal is also in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) on behalf of BARDA. The effort, which was funded under the American Rescue Plan, will enable Jubilant HollisterStier to double its injectable filling production capacity at its Spokane, WA manufacturing facility for a total cost $193 million. The project is slated completion in 2025, according to the company. The company has a history of supporting both HHS and the DOD with biodefense and medical countermeasure programs, including production for national preparedness efforts. “Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers,” Jubilant Pharma CEO Pramod Yadav said in a statement. In 2021 , Jubilant sought to expand its sterile injectable manufacturing capacity at its Spokane site to keep up with the demand surrounding the Covid-19 vaccine push. The initial $92 million investment is planned to increase manufacturing capacity by 50% with the inclusion of 2,300-square-foot lyophilizers and 50,000 square feet of building space. The upgrades will allow for 400 vials a minute to be filled. Earlier last year, the company also struck a deal with Eli Lilly for the manufacturing of bamlanivimab at the Spokane plant, however, bamlanivimab’s emergency use authorization was revoked by the FDA for the treatment of Covid-19. In 2021, the company announced that it had signed on with Novavax to provide fill-finish services to its vaccine candidate as well.